Clinical Trial Update: An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca [Phase 3]

View source ↗

Summary

Open-label extension of a phase 3 study evaluating OTX-101 for keratoconjunctivitis sicca has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Keratoconjunctivitis Sicca

Drugs mentioned

• OTX-101 (cyclosporine A 0.09% ophthalmic emulsion)

Snippet

Sponsor: Sun Pharmaceutical Industries Limited | Conditions: Keratoconjunctivitis Sicca | Phase 3 | Status: COMPLETED | Results posted: 2018-12-14